Resources

Client Alerts, News Articles, Blog Posts, & Multimedia

Everything you need to know about BMD and the industry.

President Biden Seeks to Limit Non-Compete Agreements

Client Alert

Today, President Biden announced he would issue an Executive Order that calls on the Federal Trade Commission (FTC) to adopt rules to curtail worker non-compete agreements. Interestingly, a week ago, the FTC approved changes to its Rules of Practice to modernize and expedite the way it issues Trade Regulation Rules. 

If you have followed our alerts, we predicted the elimination of non-competes would probably happen. In 2016, then-Vice President Biden was a vocal opponent against non-compete agreements. He led the Obama administration’s initiative seeking to limit or eliminate non-compete agreements. In his presidential campaign, Biden promised to “work with Congress to eliminate all non-compete agreements, except the very few that are absolutely necessary to protect a narrowly defined category of trade secrets....”

Since this is not an act of Congress, the question will be the extent and timing of any FTC rules.

The FTC enforces and administers a wide variety of federal consumer protection laws and regulations that prevent fraud, deception, and unfair business practices. It also develops policy initiatives on issues that affect competition, consumers, and the U.S. economy. 

Once the Executive Order is issued, it will be interesting to determine the authority under which the FTC will issue its rules. We anticipate that the FTC will assert authority under its broad power to protect consumers from unfair or deceptive acts or practice (“UDAP”) and unfair methods of competition (“UMC”). On January 9, 2020, the FTC held a workshop to examine whether there is a sufficient legal basis and empirical economic support to promulgate an FTC rule that would restrict the use of non-compete clauses in employer-employee employment contracts. After the workshop, the FTC extended the public comment period through March 10, 2020, but the Commission has not issued any subsequent guidance on the subject.

Stay tuned for additional information. With the announcement of the Executive Order, the outcome of the FTC non-compete analysis should soon be released. 

For additional information or strategic planning on non-competes or other restrictive covenants, contact Jeffrey C. Miller, jcmiller@bmdllc.com 216.658.2323 or any member of the BMD L+E team.


Ohio Board of Pharmacy Update: Key Regulatory Changes and Proposals You Need to Know

The Ohio Board of Pharmacy (BOP) has rescinded certain OAC rules (OAC 4729:5-18-01 through 4729:5-18-06), removing regulations on office-based opioid treatment (OBOT) clinics. The rescissions took effect on June 3, 2024. The BOP also published a new rule, OAC 4729:8-5-01, which sets explicit reporting guidelines for licensed dispensaries and became effective on June 7, 2024.

LGBTQIA+ Patients and Discrimination in Healthcare

In early April, the Kaiser Family Foundation released a study outlining the challenges that LGBT adults face in the United States related to healthcare. According to the study, LGBT patients are “twice as likely as non-LGBT adults to report negative experiences while receiving health care in the last three years, including being treated unfairly or with disrespect (33% v. 15%) or having at least one of several other negative experiences with a provider (61% v. 31%), including a provider assuming something about them without asking, suggesting they were personally to blame for a health problem, ignoring a direct request or question, or refusing to prescribe needed pain medication.”

Ohio Recovery Housing Overhaul: New Standards and Certification Requirements Reshape Sober Living Spaces

Ensuring Fair Access: SB 269 Protects Affordable Medication for Low-Income Patients

SB 269, introduced on December 19, 2023, will ensure that 340B covered entities, including Federally Qualified Health Centers, Ryan White Clinics, disproportionate share hospitals, and Title X clinics, can acquire 340B drugs without facing undue restrictions or discriminatory practices from drug manufacturers and distributors. This protection is crucial for 340B covered entities to continue to provide affordable medications and comprehensive services to low-income patients.

Unveiling Ohio's Pharmacy Board Updates for Distributors, Mobile Clinics, and Controlled Substances

The Ohio Board of Pharmacy will hold a public hearing on May 28, 2024, to discuss several proposed changes and additions to Ohio Administrative Code (OAC). These changes pertain to terminal distributors of dangerous drugs (TDDDs), mobile clinics or medication units, and the classification of controlled substances.